Aarhus, Denmark (UroToday.com) Dr. Per-Uno Malmstrom of Uppsala University presented data summarizing a twenty-year experience of outcomes from the Swedish National Registry of Urinary Bladder Cancer.
This registry, with participation mandated by local law, was started in 1997 and covers more than 95% of the Swedish patient population. Relative and observed survival from bladder cancer was stable until 2012, at which time a significant improvement up to 2017 was observed. The cystectomy rate for cT2-4 patients was around 40%, with nearly 60% of these patients foregoing radical cystectomy or curative-intent therapy for their disease. Dr. Malmstrom attributed this to advanced age or underlying frailty, and these patients experienced substantial disease-specific morbidity with an annual hospitalization rate of 2.5x/year.
Abstract take-home message:
- The Swedish National Registry of Urinary Bladder Cancer found that an improvement in survival from bladder cancer has been observed since 2012, although nearly 60% of patients in Sweden forego radical cystectomy or curative-intent therapy for their disease due to advanced age and underlying frailty.
Presented by: Per-Uno Malmstrom, MD, Ph.D., Department of Surgical Sciences, Uppsala University, Sweden
Written by: Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.